Relevant bibliographies by topics / Cheng ren jiao yu

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books

Academic literature on the topic 'Cheng ren jiao yu'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cheng ren jiao yu.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cheng ren jiao yu"

1

Hu, Jia, Jun Ni, Longxian Jiao, Jinghong Zhou, Shiming Fan, Renxiang Tang, Wei Zhang, et al. "Abstract 6321: HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models." Cancer Research 83, no. 7_Supplement (April 4, 2023): 6321. http://dx.doi.org/10.1158/1538-7445.am2023-6321.

Full text
Abstract:
Abstract Background: Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Dysregulation of FGFR signaling due to receptor fusion, mutation or amplification is observed across multiple cancer types, making activated FGFRs an important therapeutic target. Herein, we present the preclinical characterization of HMPL-453, a highly potent and selective inhibitor of FGFR1, 2, and 3, discovered and being currently developed in phase II clinical trial (NCT04353375) by HUTCHMED. Methods: Kinase activity was measured by Transcreener™ Fluorescence Polarization assay or Z’-LYTE kinase assay. In vitro anti-proliferation activity was measured by CellTiter-Glo luminescent or CCK-8 assay. The effect of HMPL-453 on FGFR signaling pathway was detected by western blot. Multiple tumor models with FGFR alteration were applied in Nu/Nu nude mice to determine anti-tumor efficacy of 453 as a single agent. A model in immune-competent BALB/c mice inoculated with the constructed NIH/3T3 cells carrying FGFR2-AHCYL1 fusion was chosen to investigate the combination effect of HMPL-453 with anti-PD-1 antibody. Results: HMPL-453 potently inhibited the tyrosine kinase activities of recombinant FGFR 1, 2, and 3 in vitro (IC50 values of 6, 4, and 6 nM, respectively) with weaker activity against FGFR4 (IC50 = 425 nM). HMPL-453 selectively inhibited proliferation of tumor cell lines with dysregulated FGFR signaling (GI50s: 3~105 nM) compared with cell lines lacking FGFR aberrations (GI50s > 1.5 µM). HMPL-453 demonstrated strong inhibition of phosphorylation of FGFR and downstream protein in tumor cell lines harboring FGFR2 fusion. Oral administration of HMPL-453 could induce time- and dose-dependent inhibition of phosphorylation of FGFR and resulted in remarkable and dose-dependent anti-tumor activity in multiple FGFR-altered tumor models. HMPL-453 at the dose of 50 mg/kg/day could induce tumor regression in most tumor models tested. Moreover, HMPL-453 significantly improved anti-tumor activity of anti-PD-1 antibody in a FGFR2 fusion model by priming the immune environment. Conclusion: HMPL-453 is a highly potent and selective inhibitor of FGFR 1, 2, and 3 with strong activity against FGFR-deregulated tumors in preclinical models, supporting continued investigation in patients with FGFR alterations (such as fusion and mutation) either as a single agent or in combination with PD-1 blockade. Citation Format: Jia Hu, Jun Ni, Longxian Jiao, Jinghong Zhou, Shiming Fan, Renxiang Tang, Wei Zhang, Xuelei Ge, Qihang Zhang, Juntao Yu, Ying Yu, Dongxia Shi, Min Cheng, Weifang Xue, Sumei Xia, Zeyu Zhong, Jian Wang, Yang Sai, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su. HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6321.
APA, Harvard, Vancouver, ISO, and other styles
2

Schmalzer, Sigrid. "Weimin Xiong;, Kedi Wang. He cheng yi ge dan bai zhi: Jie jing niu yi dao su de ren gong quan he cheng [Synthesize a protein: The story of total synthesis of crystalline insulin project in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 194 pp., figs., bibl., app., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. $25 (paper)." Isis 99, no. 1 (March 2008): 231–32. http://dx.doi.org/10.1086/589404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Xigui, Qiu. "The Early China Forum An Examination of Whether the Charges in Shang Oracle-Bone Inscriptions are Questions*." Early China 14 (1989): 77–114. http://dx.doi.org/10.1017/s0362502800002601.

Full text
Abstract:
Oracle-bone scholars have long uniformly read the charges (i.e., the portion that mentions the event being divined) of Shang oracle-bone inscriptions as questions. Since the 1970's, many foreign oracle-bone scholars have proposed a new view that the charges are never questions, or at least are generally not questions. Whether or not the charges are actually questions is a very important question bearing not only on oracle bone studies, but also on research on ancient divination and on ancient Chinese grammar. Based on an examination of a great number of Shang oracle-bone inscriptions, the author of this essay believes that charges that can now be determined to be questions are mainly those choice-type charges in early inscriptions that contain the final particles yi and zhi, and true-or-false type charges that contain yi. Charges of the type “V bu V” (such as “rain not rain” [yu bu yu]) and “V bu,” regarded by many as choice-type questions, are actually comprised of the charge and a verification or use notation, the “bu V” being a verification and the “bu” being either a verification or a use notation (similar to the notation bu yong, “do not use”). Charges that can now be determined not to be questions are mainly in those inscriptions with complex charges, such as “this *spring the king ought not ally with Wang Cheng to attack Xia Wei, (for if he does) he will not receive divine assistance” (jin ?chun wang wu bi Wang Cheng fa Xia? Wei, fu qi shou you you, and “On ren we ought not hunt, (for if we do) it will rain” (ren wu tian, qi yu), the syntax of which shows that they cannot be questions.
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Na, Jia Hu, Tingwen Li, Juntao Yu, Dongxia Shi, Min Cheng, Zeyu Zhong, et al. "Abstract 543: Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2." Cancer Research 83, no. 7_Supplement (April 4, 2023): 543. http://dx.doi.org/10.1158/1538-7445.am2023-543.

Full text
Abstract:
Abstract Background: Mutations in isocitrate dehydrogenase (IDH) 1/2 are frequently identified in various cancers, such as AML, cholangiocarcinoma, chondrosarcoma and glioma. Mutant IDHs (mIDHs) cause accumulated 2-HG, leading to blockage of cell differentiation, thereby inducing malignant transformation. Rare cases were identified carrying co-existing mutations in IDH1 and IDH2. mIDH isoform switching, from mutant IDH1 to mutant IDH2 and vice versa, have been reported as a mechanism of acquired resistance to IDH inhibition in AML and cholangiocarcinoma. Thus, simultaneous inhibition on both mIDH1 and mIDH2 may be a promising strategy to overcome resistance and improve clinical efficacy. HMPL-306, a dual inhibitor of mIDH1/mIDH2, developed by HUTCHMED, is being evaluated in clinical trials. Methods: The inhibition of HMPL-306 on IDH enzymes, including mutant and wild type, was determined by fluorescence-based assay. The selectivity of HMPL-306 was evaluated in 322 kinases (SelectScreenTM) and 88 proteins (Cerep). For cellular activities of HMPL-306, 2-HG production and differentiation were detected in cells harboring mIDH. Human tumor xenograft models carrying IDH1 or 2 mutations were established for evaluating mIDH inhibition by detecting 2-HG in plasma and tumor, and anti-tumor efficacies. Results: HMPL-306 inhibited mutant IDH enzyme activities including IDH1R132H, IDH2R140Q and IDH2R172K, while showed weaker inhibition on IDH1/2 wild type enzymes. HMPL-306 had a superior selectivity profile in a kinase panel and a safety panel, while enasidenib, an approved mIDH2 inhibitor, inhibited Adenosine-A3 with IC50 of 12 nM. In cellular assays, HMPL-306 displayed comparable activities to enasidenib and ivosidenib (approved mIDH1 inhibitor) and suppressed 2-HG through inhibition of mIDH1 or mIDH2 at similar level, indicating an equal potency against mIDH1 and 2. Moreover, in both mIDH1/2 cells, HMPL-306 reduced the levels of histone methylation, and promoted hemoglobin γ and Kruppel1 gene expression, which led to differentiation from immature malignant cells to mature normal cells. Oral administration of HMPL-306 remarkably decreased 2-HG level in plasma and tumor tissues in xenograft models carrying mIDH1 or mIDH2 and the inhibition is more potent and durable than either ivosidenib or enasidenib at the same dose. Pharmacokinetics (PK) study in rodents showed high exposures of HMPL-306 in brain and cerebrospinal fluid, a desirable feature for glioma therapy. Combination treatment of HMPL-306 and azacitidine synergized in releasing the differentiation block in mIDH AML cells. HMPL-306 also significantly improved in vivo anti-tumor efficacy of chemotherapy drugs in solid tumor models with mIDH1/2. Conclusion: HMPL-306 is a potent, dual inhibitor of IDH1/2 mutation. The strong activity and favorable PK profiles support further clinical evaluation. Citation Format: Na Yang, Jia Hu, Tingwen Li, Juntao Yu, Dongxia Shi, Min Cheng, Zeyu Zhong, Jian Wang, Yang Sai, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su. Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 543.
APA, Harvard, Vancouver, ISO, and other styles
5

Lu, Si, Yu Chen, Meiyu Fang, Zhengyun Zou, Di Wu, Zhiguo Luo, Jian Zhang, et al. "Abstract CT208: Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study." Cancer Research 83, no. 8_Supplement (April 14, 2023): CT208. http://dx.doi.org/10.1158/1538-7445.am2023-ct208.

Full text
Abstract:
Abstract Background: Immune checkpoint inhibitors (CPIs) targeting PD-(L)1 have become a standard of care for untreated, advanced melanoma, but demonstrated limited efficacy in mucosal melanoma. Tebotelimab, also known as MGD013, is a PD-1/LAG-3 bispecific tetravalent DART® molecule with synergistic antitumor activity shown in preclinical studies. We conducted an open-label, single-arm, multi-cohort phase 1 study (NCT04653038) to assess the efficacy and safety of tebotelimab in melanoma patients (pts) including those with CPI-naïve mucosal melanoma. Methods: The CPI-naïve cohort of this study enrolled pts with unresectable, recurrent or metastatic, mucosal or acral melanoma who had received no systemic therapy. Tebotelimab 600 mg was administered intravenously once every two weeks. The primary endpoint was overall response rate (ORR) assessed by independent radiologic review committee (IRC) per RECIST v1.1 in the efficacy analysis set consisting of pts who received ≥1 dose of tebotelimab. A post-hoc sensitivity analysis was conducted in the IRC-response evaluable set consisting of pts with IRC-assessed target lesions in the efficacy analysis set who received ≥1 post-baseline tumor assessment by IRC or died within 13 weeks after first dose. Results are reported for mucosal melanoma. Results: At data cut-off (January 19, 2022), 25 pts with mucosal melanoma were enrolled (median age, 61 years; male, 40%; ECOG 1, 40%; TNM Stage IV, 92%; metastatic, 80%). LAG-3 expression level was ≥1% in seven (28%), <1% in 15 (60%), and unknown in three (12%). PD-L1 expression was positive (CPS≥1) in three (12%), negative (CPS<1) in 19 (76%), and unknown in three (12%). All pts received ≥1 dose of tebotelimab. In the efficacy analysis set (n=25), three, three, and four pts achieved complete response (CR), partial response (PR), and stable disease (SD), respectively, leading to a confirmed ORR of 24% (95% confidence interval [CI], 9-45), with median duration of response (DOR) not reached, and a disease control rate (DCR) of 40% (95% CI, 21-61). In the IRC-response evaluable set (n=20), three, three, and four pts achieved CR, PR, and SD, respectively, leading to a confirmed ORR of 30% (95% CI, 12-54), with median DOR not reached, and a DCR of 50% (95% CI, 27-73). Immune-related treatment-emergent adverse events occurred in 11 (44%) pts, most commonly, hypothyroidism (20%), hyperthyroidism (16%), and white blood cell count decreased (12%). Grade ≥3 and serious treatment-related adverse events (TRAEs) were reported in three (12%) and four (16%) pts, respectively. TRAEs led to treatment discontinuation and death each in one (4%). Conclusions: Tebotelimab demonstrated preliminary but promising antitumor activity and a tolerable safety profile in pts with untreated, unresectable, recurrent or metastatic, mucosal melanoma. Citation Format: Si Lu, Yu Chen, Meiyu Fang, Zhengyun Zou, Di Wu, Zhiguo Luo, Jian Zhang, Jing Chen, Gang Huang, Hongming Pan, Xiubao Ren, Ying Cheng, Haichuan Su, Yuan Xin, Qiong Hua, Jianmei Hou, Jun Guo. Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT208.
APA, Harvard, Vancouver, ISO, and other styles
6

Drewniak, Łukasz, and Sabina Drewniak. "The influence of the oxidation method on the properties of reduced graphene oxide." Photonics Letters of Poland 14, no. 3 (September 30, 2022): 47. http://dx.doi.org/10.4302/plp.v14i3.1154.

Full text
Abstract:
Derivatives of graphene have become important materials due to their excellent properties. Graphene oxide and reduced graphene oxide are especially interesting because they are produced relatively easily, cheaply and quickly. Among many possible applications, reduced graphene oxide is a good candidate for sensor applications. Its properties can be controlled at the production stage. The precursor used and the method of oxidation have a significant influence on its properties. Therefore, it is worth take a closer look at them. In this paper we analyse the influence of the oxidation method on the size of the reduced graphene stock which determine the sensitivity of the rGO layer. We used AFM microscopy for this purpose. Full Text: PDF ReferencesS.M. Majhi, A. Mirzaei, H.W. Kim, S.S. Kim, "Reduced Graphene Oxide (rGO)-Loaded Metal-Oxide Nanofiber Gas Sensors: An Overview", Sensors 21, 4 (2021). CrossRef M. Pumera, "Graphene-based nanomaterials for energy storage", Energy Environ. Sci. 4 3 (2011). CrossRef X. Yu, H. Cheng, M. Zhang, Y. Zhao, L. Qu, G. Shi, "Graphene-based smart materials", Nat. Rev. Mater. 2, 9 (2017). CrossRef M.Y. Xia, Y. Xie, C.H. Yu, G.Y. Chen, Y.H. Li, T., Zhang, Q. Peng, "Graphene-based nanomaterials: the promising active agents for antibiotics-independent antibacterial applications", J. Control. Release 10 (2019). CrossRef X. Zhu, Y. Zhou, Y. Guo, H. Ren, C. Gao, "Nitrogen dioxide sensing based on multiple-morphology cuprous oxide mixed structures anchored on reduced graphene oxide nanosheets at room temperature", Nanotechnology 30 45 (2019). CrossRef Z. Wu, Y. Wang, S. Ying, M. Huang, C. Peng, "Fabrication of rGO/Cuprous Oxide Nanocomposites for Gas Sensing", IOP Conf. Ser.: Earth Environ. Sci. 706, 1 (2021). CrossRef S. Pei, H.M. Cheng, "The reduction of graphene oxide", Carbon 50, 9 (2012). CrossRef K. Spilarewicz-Stanek, A. Kisielewska, J. Ginter, K. Bałuszyńska, I. Piwoński, "Elucidation of the function of oxygen moieties on graphene oxide and reduced graphene oxide in the nucleation and growth of silver nanoparticles", RSC Adv. 6, 65 (2016). CrossRef R. Muzyka, S. Drewniak, T. Pustelny, M. Sajdak, Ł. Drewniak, "Characterization of Graphite Oxide and Reduced Graphene Oxide Obtained from Different Graphite Precursors and Oxidized by Different Methods Using Raman Spectroscopy Statistical Analysis", Materials 14, 4 (2021) CrossRef B. Lesiak, G. Trykowski, J. Tóth, et al. "Chemical and structural properties of reduced graphene oxide—dependence on the reducing agent", J Mater. Sci. 56 (2021). CrossRef .
APA, Harvard, Vancouver, ISO, and other styles
7

Matysiak, Wiktor, Tomasz Tański, and Weronika Monika Smok. "Morphology and structure characterization of crystalline SnO2 1D nanostructures." Photonics Letters of Poland 12, no. 3 (September 30, 2020): 70. http://dx.doi.org/10.4302/plp.v12i3.1019.

Full text
Abstract:
In recent years, many attempts have been made to improve the sensory properties of SnO2, including design of sensors based on one-dimensional nanostructures of this material, such as nanofibers, nanotubes or nanowires. One of the simpler methods of producing one-dimensional tin oxide nanomaterials is to combine the electrospinning method with a sol-gel process. The purpose of this work was to produce SnO2 nanowires using a hybrid electrospinning method combined with a heat treatment process at the temperature of 600 °C and to analyze the morphology and structure of the one-dimensional nanomaterial produced in this way. Analysis of the morphology of composite one-dimensional tin oxide nanostructures showed that smooth, homogeneous and crystalline nanowires were obtained. Full Text: PDF ReferencesN. Dharmaraj, C.H. Kim, K.W. Kim, H.Y. Kim, E.K. Suh, "Spectral studies of SnO2 nanofibres prepared by electrospinning method", Spectrochim. Acta - Part A Mol. Biomol. Spectrosc. 64, (2006) CrossRef N. Gao, H.Y. Li, W. Zhang, Y. Zhang, Y. Zeng, H. Zhixiang, ... & H. Liu, "QCM-based humidity sensor and sensing properties employing colloidal SnO2 nanowires", Sens. Actuators B Chem. 293, (2019), 129-135. CrossRef W. Ge, Y. Chang, V. Natarajan, Z. Feng, J. Zhan, X. Ma, "In2O3-SnO2 hybrid porous nanostructures delivering enhanced formaldehyde sensing performance", J.Alloys and Comp. 746, (2018) CrossRef M. Zhang, Y. Zhen, F. Sun, C. Xu, "Hydrothermally synthesized SnO2-graphene composites for H2 sensing at low operating temperature", Mater. Sci. Eng. B. 209, (2016), 37-44. CrossRef Y. Zhang, X. He, J. Li, Z. Miao, F. Huang, "Fabrication and ethanol-sensing properties of micro gas sensor based on electrospun SnO2 nanofibers", Sens. Actuators B Chem. 132, (2008), 67-73. CrossRef W.Q. Li, S.Y. Ma, J. Luo, Y.Z. Mao, L. Cheng, D.J. Gengzang, X.L. Xu, S H. Yan, "Synthesis of hollow SnO2 nanobelts and their application in acetone sensor", Mater. Lett. 132, (2014), 338-341. CrossRef E. Mudra, I. Shepa, O. Milkovic, Z. Dankova, A. Kovalcikova, A. Annusova, E. Majkova, J. Dusza, "Effect of iron doping on the properties of SnO2 nano/microfibers", Appl. Surf. Sci. 480, (2019), 876-881. CrossRef P. Mohanapriya, H. Segawa, K. Watanabe, K. Watanabe, S. Samitsu, T.S. Natarajan, N.V. Jaya, N. Ohashi, "Enhanced ethanol-gas sensing performance of Ce-doped SnO2 hollow nanofibers prepared by electrospinning", Sens. Actuators B Chem. 188, (2013), 872-878. CrossRef W.Q. Li, S.Y. Ma, Y.F. Li, X.B. Li, C.Y. Wang, X.H. Yang, L. Cheng, Y.Z. Mao, J. Luo, D.J. Gengzang, G.X. Wan, X.L. Xu, "Preparation of Pr-doped SnO2 hollow nanofibers by electrospinning method and their gas sensing properties", J.Alloys and Comp. 605, (2014), 80-88. CrossRef X.H. Xu, S.Y. Ma, X.L. Xu, T. Han, S.T. Pei, Y. Tie, P.F. Cao, W.W. Liu, B.J. Wang, R. Zhang, J.L. Zhang, "Ultra-sensitive glycol sensing performance with rapid-recovery based on heterostructured ZnO-SnO2 hollow nanotube", Mater. Lett, 273, (2020), 127967. CrossRef F. Li, X. Gao, R. Wang, T. Zhang, G. Lu, Sens. "Study on TiO2-SnO2 core-shell heterostructure nanofibers with different work function and its application in gas sensor", Actuators B Chem, 248, (2017), 812-819. CrossRef S. Bai, W. Guo, J. Sun, J. Li, Y. Tian, A. Chen, R. Luo, D. Li, "Synthesis of SnO2–CuO heterojunction using electrospinning and application in detecting of CO", Sens Actuators B Chem, 226, (2016), 96-103. CrossRef H. Du, P.J. Yao, Y. Sun, J. Wang, H. Wang, N. Yu, "Electrospinning Hetero-Nanofibers In2O3/SnO2 of Homotype Heterojunction with High Gas Sensing Activity", Sensors, 17, (2017), 1822. CrossRef X. Wang, H. Fan, P. Ren, "Electrospinning derived hollow SnO2 microtubes with highly photocatalytic property", Catal. Commun. 31, (2013), 37-41. CrossRef L. Cheng, S.Y. Ma, T.T. Wang, X.B. Li, J. Luo, W.Q. Li, Y.Z. Mao, D.J Gengzang, "Synthesis and characterization of SnO2 hollow nanofibers by electrospinning for ethanol sensing properties", Mater. Lett. 131, (2014), 23-26. CrossRef P.H. Phuoc, C.M. Hung, N.V. Toan, N.V. Duy, N.D. Hoa, N.V. Hieu, "One-step fabrication of SnO2 porous nanofiber gas sensors for sub-ppm H2S detection", Sens. Actuators A Phys. 303, (2020), 111722. CrossRef A.E. Deniz, H.A. Vural, B. Ortac, T. Uyar, "Gold nanoparticle/polymer nanofibrous composites by laser ablation and electrospinning", Matter. Lett. 65, (2011), 2941-2943. CrossRef S. Sagadevan, J. Podder, "Investigation on Structural, Surface Morphological and Dielectric Properties of Zn-doped SnO2 Nanoparticles", Mater. Res. 19, (2016), 420-425. CrossRef
APA, Harvard, Vancouver, ISO, and other styles
8

Jing, Yu, Ying Li, Liping Dou, Shengjuan Zhang, Ran Tian, Guojing Wang, Xiangrui Cheng, et al. "Abstract CT180: Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia." Cancer Research 84, no. 7_Supplement (April 5, 2024): CT180. http://dx.doi.org/10.1158/1538-7445.am2024-ct180.

Full text
Abstract:
Abstract Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy has shown remarkable responses in hematologic malignancies. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptive transferred CAR-T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment. We previously developed CD19CAR-T cells secreting PD-1Ab21 fusion protein composed of anti-PD-1 single chain antibody and IL-21(PD-1Ab21-CD19CAR-T). This investigator-initiated clinical trial is designed to assess the safety and efficacy of the novel CAR-T cells in advanced relapsed/refractory acute Lymphoblastic leukemia (ALL). Methods: This study recruited 10 patients with advanced relapsed/refractory B-ALL and half of them relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). All patients received fludarabine and cyclophosphamide before a single infusion of PD-1Ab21-CD19CAR-T cells at dose of 0.3, 1 or 3 x 106 cells/kg of body weight. The patients were monitored for adverse events, clinical response, as well as expansion of CAR-T and lymphocytes. Results: All five non-post-transplant patients achieved complete remission (CR), including two active CNS diseases, and three of them pursued consolidative allo-HSCT. Among the five post-transplant patients, one patient, who had undergone autologous, allogeneic CAR-T cell therapies and allo-HSCT, achieved CR and remained leukemia-free for 5 months, which was longer than the duration of remission (< 4 monthes) after allo-HSCT. The last treated patient achieved CR. Three other post-transplant patients, including two active CNS diseases, eventually died of the infection. One of the patients achieved minimal residual disease negative CR. The other two patients did not undergo laboratory evaluation, but their CNS symptoms disappeared. Once the expansion of CAR-T cells was detected, the proportion of CD8+T cell in CD3+T cells increased dramatically, rapidly reaching 77.8~91.2% and maintaining above 50% for a long time in all treated patients. Except for the three patients who died from infection, other patients experienced no or mild cytokine release syndrome (CRS) (grade ≤2). None of the patients had neurotoxic side effects. Conclusion: This study demonstrates that PD-1Ab21-secreting CAR-T cells are safe and effective therapeutic platform, even in cancer patients with CNS invasion. Our data also suggest that PD-1Ab21-secreting CAR-T therapy can activate endogenous anti-tumor CD8+ T cell responses. Citation Format: Yu Jing, Ying Li, Liping Dou, Shengjuan Zhang, Ran Tian, Guojing Wang, Xiangrui Cheng, Jitao Zhao, Hang Li, Yueyi An, Naibo Yang, Shengdian Wang. Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT180.
APA, Harvard, Vancouver, ISO, and other styles
9

Lewis, John W., and Xue Litai. "Jifeng Liu;, Yanqiong Liu;, Haiyan Xie. Liang dan yi xing gong cheng yu da ke xue [The Project of “Two Bombs, One Satellite”: A Model of the Big Science]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 254 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. ¥27 (paper)." Isis 99, no. 2 (June 2008): 430–31. http://dx.doi.org/10.1086/591370.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yang, Xianwen, Guiping Li, Peiling Ren, Xiaoyun Shi, Ying Yu, Baoyu Hao, Pan Wang, Min Cheng, and Guangxiu Dai. "Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells." Cancer Research 84, no. 6_Supplement (March 22, 2024): 1931. http://dx.doi.org/10.1158/1538-7445.am2024-1931.

Full text
Abstract:
Abstract Many TEAD small-molecule inhibitors (SMIs) have recently reported initial clinical evaluations on Hippo-mutated cancer types. Several studies have demonstrated that activation of the YAP1/TEAD transcriptional complex via a Hippo-independent manner can drive resistance to MAPK/ERK pathway inhibitors. Here, we elucidated the potential mechanism of TEAD inhibition overcoming MAPK/ERK pathway resistance with a TEAD SMI (hereafter abbreviated as TEADi). Firstly, the MoA of TEADi was validated in Hippo-mutated cells. TEADi inhibited cell growth of Hippo-mutated cancer cell lines NCI-H226 and NCI-H2052 but not that of MKN45, a YAP1-deletion cell line. Co-IP and qRT-PCR results demonstrated that TEADi disrupted the interaction between YAP1 and TEAD, and thus markedly repressed the expression of CTGF and CYR61, two downstream targets of YAP1/TEAD, in NCI-H226 cells. Secondly, we hypothesized that hyper-activation of TEAD confers resistance to KRAS mutant cancer types. To test this hypothesis, we generated two resistant cell lines. One is KARS G12C inhibitor Sotorasib-resistant NCI-H358 (NCI-H358-R). The other is MEK inhibitor Trametinib-resistant HCT116 (HCT116-R). Immunofluoresence assay showed that YAP1 nucleus translocation was enhanced in both resistant cells (NCI-H358-R and HCT116-R), but not in their parental counterparts (NCI-H358-P and HCT116-P). The enhanced YAP1 nucleus translocation resulted in increased transcription activities of TEAD in both resistant cells, as illustrated by luciferase reporter assay. Accordingly, CTGF and CYR61 were observed upregulated in both resistant cells. The above data indicate that YAP1/TEAD mediated-transactivation plays a role in MAPK pathway resistance. Indeed, TEADi treatment alone displayed substantial difference in cell growth inhibition between parental and resistant cell lines in both NCI-H358 and HCT116, further confirming that the resistant cells are more dependent on YAP1/TEAD signaling. Finally, we evaluated the combinational efficacies of TEADi and MAPK/ERK pathway inhibitors in the resistant cells. It was observed that addition of TEADi could significantly restore the response of NCI-H358-R and HCT116-R to Sotorasib and Trametinib, respectively. Mechanistically, TEADi efficiently suppressed TEAD transcriptional activities and subsequently the expression of CTGF and CYR61 in both resistant cells. Moreover, TEADi had almost no impact on ERK phosphorylation in either of the resistant cells, suggesting that re-sensitization of MAPK/ERK pathway inhibitors by TEADi is independent of primary onco-genetic signaling pathway. Taken together, our study demonstrates that inhibition of YAP1/TEAD signaling would be an efficient approach to overcome resistance to MAPK/ERK pathway inhibitors in the patients carrying KRAS mutations, and provides the scientific basis for development of combination therapy strategies. Citation Format: Xianwen Yang, Guiping Li, Peiling Ren, Xiaoyun Shi, Ying Yu, Baoyu Hao, Pan Wang, Min Cheng, Guangxiu Dai. Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1931.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cheng ren jiao yu"

1

Chow, Chiu Tuen. "Shan yu e : Mengzi yu Xunzi ren xing lun zhi bi jiao /." View abstract or full-text, 2007. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202007%20CHOW.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Meng, Shuhui. "Zhu Xi ji qi men ren de jiao hua li nian yu shi jian /." Tai Bei : Guo li Tai Wan da xue, 2003. http://catalogue.bnf.fr/ark:/12148/cb39292461m.

Full text
Abstract:
Th. doct.--histoire--Taibei--National Taiwan University = Guo li Tai Wan da xue, 2001.
Mention parallèle de titre ou de responsabilité : Instruction in virtue and its practice by Chu Hsi and his disciples. Bibliogr. p. 441-458.
APA, Harvard, Vancouver, ISO, and other styles
3

Lam, Tung-fei, and 林同飛. "Strategies teachers used to adapt materials of second language Chinese in the International Baccalaureate Diploma Programme : enacting international mindedness? = Guo ji wen ping yu ke ke cheng di er yu yan Han yu ke jiao shi diao shi jiao cai de ce lüe : shi jian guo ji yi shi?" Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/209525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yu, Xiulan. "Zhongguo jiao yu de cheng xiang cha yi yi zhong wen hua zai sheng chan xian xiang de fen xi = Zhongguo jiaoyu de chengxiang chayi /." Beijing : Jiao yu ke xue chu ban she, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Siu, King-wai. "Dating the extant version of the Kongzi Jiayu a linguistic and textual exploration = Jin ben"Kongzi jia yu" cheng shu nian dai xin kao: cong yu yan ji wen xian jiao du kao cha /." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/HKUTO/record/B38628636.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Poon, Hon-fong. "Dating the extant version of Kongcongzi a linguistic exploration = Jin ben Kong cong zi cheng shu nian dai xin kao : cong yu yan jiao du de kao cha /." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40987905.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ouyang, Sutong. "Leng zhan shi dai de shi jie wei ji yu Meiguo de ze ren : dui Laiyinhuoerde Nibuer hou qi zheng zhi shen xue de yan jiu = World crisis in cold war and American responsibility : on Reinhold Niebuhr's later political theology /." click here to view the abstract and table of contents click here to view the fulltext, 2005. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b1884280xa.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dawacairen. "Dang dai Xizang de huo fo : xin tu ren tong, zheng zhi jiao se yu she hui ying xiang = Living Buddhas in contemporary Tibet : believers' identifications, political roles and social influence /." click here to view the abstract and table of contents click here to view the fulltext, 2004. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b18515599a.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chow, Ka-kin Kelvin, and 周家建. "A study of the Chinese Canadians identity and social status in comparison with other minority ethnic groups in the 20th Century = 20 shi ji Jianada Hua ren yu qi ta shao shu zu yi de she hui shen fen yu di wei bi jiao." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/202365.

Full text
Abstract:
In tracing the experience of Chinese Canadians in the 20th Century, we need to look further back into its history. Most people believe that the increasing number of immigrants from Hong Kong, Taiwan and China in the 1980s and 1990s played the most important roles in the social and economic changes during the latest decades of the 20th Century. The contribution of the Chinese Canadians settlement throughout the 20th Century should also be considered as it marks the beginning of the rise of their social status and identity in Canada. Although the Chinese Canadians earned their fame and status since the 1980s, they had been racially discriminated for more than a century. To probe into the situation, the social and political situations in the Chinese Canadian community will be meticulously analyzed and their contribution in difference aspects examined. In addition, other minority ethnic groups, such as the Japanese, Jewish and Indian, will be used as a comparison to demonstrate the change of policies towards the Chinese in Canada. In doing so, both English and Canadian Chinese newspapers will be used to illustrate the cultural difference between the “whites” and “non-whites”. To illustrate the changes, the 20th Century will be break into three parts. In most of the pre-Second World War period, the Chinese community was isolated from the mainstream community with their activities largely confined to Chinatowns in cities, such as Vancouver, Victoria, Toronto and so on. For the Chinese living in small townships, such as Prince Rupert, Richmond and so on, their daily life will also be examined. When Canada declared war on Japan on 7th December 1941, Canada became an ally of China during the war. A sentiment of acceptance of the Chinese in the mainstream society began to take shape. Some of the Chinese chose to contribute their efforts to Canada by joining the Canadian Armed Forces and went into battle alongside the White Canadians. After the Second World War, Canada adopted a new policy towards the minority ethnic groups and Chinese Canadians started to enjoy political equality. In May 1947, the Canadian Government repealed the Chinese Immigration Act. In 1967, after the liberalization of the Canadian immigration policy, the Chinese, once again, were allowed to immigrate freely to Canada as an individual. With granted full citizenship, the Chinese social and political status began to change. In 1957, Douglas Jung, a Canadian born Chinese, was elected a Member of the Parliament, which can be seen as the beginning of the Chinese involvement in the political arena of the Canadian community. Since then, Chinese Canadians were able to achieve equality in the society. Based on documentary accounts and oral history research, this thesis re-constructed the history of Canadian Chinese involvement in the 20th Century and the change of their identity and social status thereafter.
published_or_final_version
Social Work and Social Administration
Doctoral
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Jianjun. "He zuo de ke cheng bian ge zhong de jiao shi zhuan ye fa zhan Shanghai Shi "Xin ji chu jiao yu shi yan" ge an yan jiu = The professional development of teachers involved in collaborative curriculum change : the case of New Basic Education Project in Shanghai /." online access from Digital dissertation consortium, 2002. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3066599.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cheng ren jiao yu"

1

Chang, Daozhi. Cheng ren jiao yu. [Beijing: Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1890-1952, Ren Baitao, ed. Cheng ren jiao yu. [Beijing: Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Yaochang. Cheng ren jiao yu. [Beijing: Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

ming, Wang yi. She jiao yu cheng gong. Guang zhou: Ling nan mei zhu chu ban she, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1957-, Hua Cheng, and Zhang Shiping, eds. Cheng ren jiao yu shi. Haikou Shi: Hainan chu ban she, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wenying, Wu, ed. Cheng ren jiao yu xue. Gaoxiong Shi: Li wen wen hua shi ye gu fen you xian gong si, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhongguo jiao yu xue hui (Beijing, China). Jiao yu yan jiu hui, ed. Cheng ren jiao yu xue. Fuzhou: Fujian jiao yu chu ban she, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shixiong, Guan, and Zhang Nianhong, eds. Cheng ren jiao yu shou ce. Beijing: Beijing chu ban she, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tang, Yiping. Cheng ren gao deng jiao yu xue shi xue wei ying yu kao shi zong he jiao cheng. Shanghai: Shang hai shi jie tu shu chu ban gong si, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhao, Yan. Meiguo xiang cun cheng ren jiao yu. Beijing: Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Cheng ren jiao yu' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography